Many GBM drugs have been developed to target the Bcl2 pathway, for example, ABT-737 inhibits both Bcl2 and Bcl-XL, and can induce apoptosis of GBM in vitro and in vivo [14]. The gene discussed is BCL2; the disease is glioblastoma.